Healthcare & biotech
Healthcare and biotech deals on OBC prioritize clinically or commercially validated models, avoiding pure pre-clinical scientific risk unless expressly disclosed.
Ticket size, term, exit mechanics and reporting are all shaped in the specialist conversation we have with you. What you see here is our default posture per sector — the final terms are tailored to your strategy call and the deal-qualification call before you commit.
- Digital health and care-delivery platforms
- Medical devices with regulatory clearance
- Diagnostics and specialty services
- Selective late-stage biotech with data readouts
- Equity SPV with milestone tranching where relevant
- IP-secured collateral for asset-heavy plays
- Regulatory-milestone reporting
- Escrow-based funding
The process, step by step
The same 4 stages apply to every healthcare & biotech deal — with escrow release only after shares are transferred to investors.
- 01
Sourcing
Specialist advisors and healthcare operators.
- 02
Diligence
Clinical, regulatory, reimbursement and IP review.
- 03
Structuring
Tranches aligned with regulatory milestones.
- 04
Deployment
Wire from escrow after documentation completes.
Key risks to consider
No investment is risk-free. These are the primary risk categories we assess for healthcare & biotech deals.
- Regulatory approval risk
- Reimbursement and payer risk
- Clinical / commercial adoption